Characterization of Salmonella enterica Derivatives Harboring Defined aroC and Salmonella Pathogenicity Island 2 Type III Secretion System ( ssaV ) Mutations by Immunization of Healthy Volunteers

• DOI: 10.1128/iai.70.7.3457-3467.2002
• Publication Date: 2002-07-27T10:09:14Z
• Authors: Zoë Hindle; Steven N. Chatfield; Jo Phillimore; Matthew Bentley; Julie Johnson; Catherine A. Cosg...; Marjan Ghaem-Maghami; Amy Sexton; Mohammad Khan; Frank R. Brennan; Paul Everest; Tao Wu; Derek Pickard; David W. Holden; Gordon Dougan; George E. Griffin; Deborah House; Joseph D. Santangelo; Shahid A. Khan; Jaqueline E. Shea; Robert G. Feldman; David J. M. Lewis
• Keywords: Salmonella enterica; Antibody titer

ABSTRACT The attenuation and immunogenicity of two novel Salmonella vaccine strains, enterica serovar Typhi (Ty2 Δ aroC ssaV , designated ZH9) S. Typhimurium (TML WT05), were evaluated after their oral administration to volunteers as single escalating doses 10 7 8 or 9 CFU. ZH9 was well tolerated, not detected in blood, nor persistently excreted stool. Six nine elicited anti-serovar lipopolysaccharide (LPS) immunoglobulin A (IgA) antibody-secreting cell (ASC) responses, with three vaccinees receiving CFU which high-titer LPS-specific serum IgG. WT05 also tolerated no diarrhea, although the resulted shedding stools for up 23 days. Only immunized mounted detectable ASC responses antibody variable. These data indicate that mutations type III secretion systems may provide a route development live vaccines humans highlight significant differences potential use serovars Typhi.